How to buy Bellicum Pharmaceuticals stock (BLCM)

Bellicum Pharmaceuticals is a biotechnology business based in the US. Bellicum Pharmaceuticals shares (BLCM) are listed on the PINK and all prices are listed in US Dollars. Bellicum Pharmaceuticals employs 13 staff and has a trailing 12-month revenue of around $1.5 million.

Our top picks for where to buy Bellicum Pharmaceuticals stock

Buy Bellicum Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Bellicum Pharmaceuticals stock price (PINK: BLCM)

Use our graph to track the performance of BLCM stocks over time.

Bellicum Pharmaceuticals shares at a glance

• Key figures

Information last updated 2024-04-04.

52-week range	$0.07 - $0.24
50-day moving average more info button	$0.11
200-day moving average more info button	$0.26
Wall St. target price	$5.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.67

Bellicum Pharmaceuticals financials

Revenue TTM	$1.5 million
Gross profit TTM	$-17,378,000
Return on assets TTM	-78.1%
Return on equity TTM	-148.5%
Profit margin	0%
Book value	$-2.78
Market Capitalization more info button	$778,326

TTM: trailing 12 months

Bellicum Pharmaceuticals share dividends

We're not expecting Bellicum Pharmaceuticals to pay a dividend over the next 12 months.

Have Bellicum Pharmaceuticals's shares ever split?

Bellicum Pharmaceuticals's shares were split on a 1:10 basis on 5 February 2020 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Bellicum Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Bellicum Pharmaceuticals shares which in turn could have impacted Bellicum Pharmaceuticals's share price.

Bellicum Pharmaceuticals share price volatility

Over the last 12 months, Bellicum Pharmaceuticals's shares have ranged in value from as little as $0.065 up to $0.24. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (PINK average) beta is 1, while Bellicum Pharmaceuticals's is 1.382. This would suggest that Bellicum Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Bellicum Pharmaceuticals overview

Bellicum Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc. ; BioVec Pharma, Inc. ; ARIAD Pharmaceuticals, Inc.

Frequently asked questions

null
What percentage of Bellicum Pharmaceuticals is owned by insiders or institutions?
Currently 0.987% of Bellicum Pharmaceuticals shares are held by insiders and 32.908% by institutions. How many people work for Bellicum Pharmaceuticals?
Latest data suggests 13 work at Bellicum Pharmaceuticals. When does the fiscal year end for Bellicum Pharmaceuticals?
Bellicum Pharmaceuticals's fiscal year ends in December. Where is Bellicum Pharmaceuticals based?
Bellicum Pharmaceuticals's address is: 3730 Kirby Drive, Houston, TX, United States, 77098 What is Bellicum Pharmaceuticals's ISIN number?
Bellicum Pharmaceuticals's international securities identification number is: US0794814048 What is Bellicum Pharmaceuticals's CUSIP number?
Bellicum Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 079481404